Compare Stocks: PTCT, GMAB, UTHR, and ASND

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$260.81 -3.4%	$257.91	$186.05 ▼ $282.15	$16.85B	0.35	525,318 shs	476,161 shs
GMAB Genmab A/S	$33.04 -1.5%	$30.85	$23.62 ▼ $35.43	$20.92B	0.84	2.49 million shs	2.13 million shs
PTCT PTC Therapeutics	$67.57 -1.8%	$75.02	$57.47 ▼ $90.87	$5.74B	0.55	766,141 shs	1.07 million shs
UTHR United Therapeutics	$506.82 +1.8%	$523.12	$395.00 ▼ $609.35	$21.36B	0.56	464,691 shs	475,587 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	-3.44%	-2.43%	+2.03%	+20.97%	+28.54%
GMAB Genmab A/S	-1.46%	-3.45%	+7.03%	+30.90%	+18.72%
PTCT PTC Therapeutics	-1.80%	-5.88%	-9.46%	-9.56%	+15.66%
UTHR United Therapeutics	+1.78%	+3.01%	-4.31%	-7.07%	+25.51%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$260.81 -3.4%	$257.91	$186.05 ▼ $282.15	$16.85B	0.35	525,318 shs	476,161 shs
GMAB Genmab A/S	$33.04 -1.5%	$30.85	$23.62 ▼ $35.43	$20.92B	0.84	2.49 million shs	2.13 million shs
PTCT PTC Therapeutics	$67.57 -1.8%	$75.02	$57.47 ▼ $90.87	$5.74B	0.55	766,141 shs	1.07 million shs
UTHR United Therapeutics	$506.82 +1.8%	$523.12	$395.00 ▼ $609.35	$21.36B	0.56	464,691 shs	475,587 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	-3.44%	-2.43%	+2.03%	+20.97%	+28.54%
GMAB Genmab A/S	-1.46%	-3.45%	+7.03%	+30.90%	+18.72%
PTCT PTC Therapeutics	-1.80%	-5.88%	-9.46%	-9.56%	+15.66%
UTHR United Therapeutics	+1.78%	+3.01%	-4.31%	-7.07%	+25.51%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASND Ascendis Pharma A/S	3.05	Buy	$310.05	18.88% Upside
GMAB Genmab A/S	2.85	Moderate Buy	$39.50	19.55% Upside
PTCT PTC Therapeutics	2.64	Moderate Buy	$98.55	45.84% Upside
UTHR United Therapeutics	2.85	Moderate Buy	$646.00	27.46% Upside

Current Analyst Ratings Breakdown

Latest PTCT, GMAB, UTHR, and ASND Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	ASND Ascendis Pharma A/S	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
9/1/2026	ASND Ascendis Pharma A/S	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$304.00 ➝ $312.00
9/1/2026	GMAB Genmab A/S	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
9/1/2026	PTCT PTC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
9/1/2026	ASND Ascendis Pharma A/S	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$275.00 ➝ $273.00
9/1/2026	ASND Ascendis Pharma A/S	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$327.00
8/31/2026	ASND Ascendis Pharma A/S	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$333.00 ➝ $330.00
8/31/2026	ASND Ascendis Pharma A/S	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$328.00 ➝ $326.00
8/31/2026	ASND Ascendis Pharma A/S	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$345.00
8/31/2026	ASND Ascendis Pharma A/S	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$306.00 ➝ $304.00
8/27/2026	UTHR United Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASND Ascendis Pharma A/S	$814.57M	19.97	N/A	N/A	($2.97) per share	-87.81
GMAB Genmab A/S	$3.72B	5.54	$1.59 per share	20.83	$9.10 per share	3.63
PTCT PTC Therapeutics	$1.01B	5.59	$8.62 per share	7.84	($2.56) per share	-26.39
UTHR United Therapeutics	$3.18B	6.83	$33.56 per share	15.10	$164.81 per share	3.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASND Ascendis Pharma A/S	-$258M	$12.89	20.23	29.30	N/A	70.99%	32.54%	7.71%	11/11/2026 (Estimated)
GMAB Genmab A/S	$963M	$1.27	26.02	20.78	1.89	19.08%	14.89%	7.73%	11/5/2026 (Estimated)
PTCT PTC Therapeutics	$682.64M	-$0.58	N/A	31.72	2.12	-3.80%	-362.45%	-1.32%	11/3/2026 (Estimated)
UTHR United Therapeutics	$1.33B	$27.95	18.13	17.08	2.49	41.56%	20.18%	17.98%	11/4/2026 (Estimated)

Latest PTCT, GMAB, UTHR, and ASND Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	ASND Ascendis Pharma A/S	$1.71	$1.0270	-$0.6830	$3.23	$376.75 million	$387.22 million
8/6/2026	Q2 2026	GMAB Genmab A/S	$0.37	$0.54	+$0.17	$0.4910	$1.12 billion	$1.16 billion
8/5/2026	Q2 2026	UTHR United Therapeutics	$6.86	$7.27	+$0.41	$7.27	$804.65 million	$783.30 million
7/30/2026	Q2 2026	PTCT PTC Therapeutics	$0.2363	$0.92	+$0.6837	$0.92	$298.63 million	$360.52 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASND Ascendis Pharma A/S	0.27	2.99	2.32
GMAB Genmab A/S	0.81	2.46	2.44
PTCT PTC Therapeutics	N/A	3.39	3.28
UTHR United Therapeutics	N/A	5.73	5.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASND Ascendis Pharma A/S	N/A
GMAB Genmab A/S	7.07%
PTCT PTC Therapeutics	N/A
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
ASND Ascendis Pharma A/S	40.00%
GMAB Genmab A/S	1.54%
PTCT PTC Therapeutics	5.30%
UTHR United Therapeutics	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASND Ascendis Pharma A/S	1,189	62.38 million	37.43 million	Optionable
GMAB Genmab A/S	3,119	623.78 million	614.17 million	Optionable
PTCT PTC Therapeutics	1,410	83.46 million	79.04 million	Optionable
UTHR United Therapeutics	1,400	42.89 million	39.20 million	Optionable

PTCT, GMAB, UTHR, and ASND Headlines

Recent News About These Companies

Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

48 minutes ago | insidertrades.com

Amundi Acquires 71,495 Shares of United Therapeutics Corporation $UTHR

2 hours ago | marketbeat.com

United Therapeutics : une dirigeante cède des actions pour un montant de 4 740 795 dollars, selon une déclaration à la SEC

September 9 at 6:44 PM | zonebourse.comZ

Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest

September 9 at 6:44 PM | finance.yahoo.com

United Therapeutics Corporation (UTHR) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

September 9 at 6:44 PM | seekingalpha.com

United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

September 9 at 5:06 PM | marketbeat.com

United Therapeutics enters $477.6M accelerated share repurchase

September 8 at 5:39 PM | msn.com

United Therapeutics Announces New Accelerated Share Repurchase

September 8 at 5:30 PM | tipranks.com

Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

September 8 at 5:07 PM | marketbeat.com

United Therapeutics Corporation (UTHR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

September 8 at 3:00 PM | seekingalpha.com

United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization

September 8 at 7:32 AM | markets.ft.com

California State Teachers Retirement System Grows Stake in United Therapeutics Corporation $UTHR

September 8 at 4:24 AM | marketbeat.com

Hsbc Holdings PLC Raises Stake in United Therapeutics Corporation $UTHR

September 8 at 3:52 AM | marketbeat.com

16,970 Shares in United Therapeutics Corporation $UTHR Purchased by Nykredit A S

September 6, 2026 | marketbeat.com

United Therapeutics (NASDAQ:UTHR) CEO Sells $4,687,870.00 in Stock

September 6, 2026 | americanbankingnews.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells $4,000,849.00 in Stock

September 6, 2026 | americanbankingnews.com

Odyssean LLC Purchases 2,358 Shares of United Therapeutics Corporation $UTHR

September 5, 2026 | marketbeat.com

United Therapeutics (UTHR) Down 8% Since Last Earnings Report: Can It Rebound?

September 4, 2026 | zacks.com

United Therapeutics (NASDAQ:UTHR) EVP Sells 8,300 Shares

September 4, 2026 | insidertrades.com

United Therapeutics (NASDAQ:UTHR) Stock Price Down 4.7% on Insider Selling

September 4, 2026 | americanbankingnews.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells 8,300 Shares of Stock

September 3, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTCT, GMAB, UTHR, and ASND Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

$260.81 -9.28 (-3.44%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$260.45 -0.36 (-0.14%)

As of 05:46 AM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Genmab A/S NASDAQ:GMAB

$33.04 -0.49 (-1.46%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$32.72 -0.32 (-0.97%)

As of 05:50 AM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

PTC Therapeutics NASDAQ:PTCT

$67.57 -1.24 (-1.80%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$67.94 +0.37 (+0.54%)

As of 04:06 AM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

United Therapeutics NASDAQ:UTHR

$506.82 +8.85 (+1.78%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$507.07 +0.25 (+0.05%)

As of 09/9/2026 07:30 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PTCT, GMAB, UTHR, and ASND Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PTCT, GMAB, UTHR, and ASND Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PTCT, GMAB, UTHR, and ASND Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTCT, GMAB, UTHR, and ASND Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

Genmab A/S NASDAQ:GMAB

PTC Therapeutics NASDAQ:PTCT

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PTCT, GMAB, UTHR, and ASND Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PTCT, GMAB, UTHR, and ASND Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PTCT, GMAB, UTHR, and ASND Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTCT, GMAB, UTHR, and ASND Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

Genmab A/S NASDAQ:GMAB

PTC Therapeutics NASDAQ:PTCT

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools